Clinical trial
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
NCT00082017 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00082017 |
|---|---|
| Title | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas |
| Official title | Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large-Cell, Ki-1, T-Cell |
| Intervention type | Drug |
| Interventions | UCN-01 (7-hydroxystaurosporine) |
| Enrollment | 20 |
| Start date | Apr 5, 2004 |
| Primary completion | Sep 27, 2011 |
| Completion | Sep 27, 2011 |
| First posted | Apr 28, 2004 |
| Last update posted | May 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: